Drug intelligence / Profile preview

BnH-015B

Development stage: Phase 1
Lead developer: BnH Research
Modality: Small Molecules
Administration: Oral

Overview

BnH-015B is a novel small molecule compound developed by BnH Research for the treatment of Alzheimer's disease. It acts as a positive modulator targeting the GluN2B binding site on N-methyl-D-aspartate (NMDA) receptors, aiming to regulate glutamatergic neurotransmission. Preclinical studies suggest that BnH-015B improves cognitive decline symptoms by modulating brain-derived neurotrophic factor (BDNF)/TRKβ and microglia-mediated IL-33/osteopontin (OPN) signaling pathways. The drug is currently in phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with moderate Alzheimer's disease[1][2][3][4].

Targets

GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)

Beyond the preview

Go deeper on BnH-015B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BnH-015B.

Explore the full profile